The study investigated the neoadjuvant treatment of GOLP (gemcitabine, oxaliplatin, L-asparaginase and poly I:C) in patients with resectable high-risk intrahepatic cholangiocarcinoma (iCCA). Treatment was given before surgery to reduce the risk of recurrence. The results showed a lower percentage of resections with positive tumor margins compared to standard care. Positive margins mean that the tumor cells remained at the edge of the removed tissue during the operation. The study was published in the New England Journal of Medicine (Volume 394, Number 10, Pages 983-995). These findings suggest the potential of neoadjuvant chemotherapy in improving surgical outcomes in iCCA. The study highlights the need for more research to confirm long-term benefits.[1]